Myan NV (NASDAQ:MYL) is to launch two new low-cost HIV combination treatments in the US after winning approval from the Food and Drug Administration.
Symfi Lo will be introduced in the coming weeks and Cimduo will be released in the second quarter.
The treatments aim to address the high cost of other HIV therapies, which account for more than US$20bn in annual spending, the company said.
Mylan is the world’s largest provider of HIV/AID treatments. It treats more than 40% of the 20 million patients across the globe.
In 2016 Mylan came under fire for raising the price of anti-allergy treatment, EpiPen, which saw chief executive Heather Bresch face tough questioning by a House Oversight Committee.